Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action

Kelly Allott^{1

2}, Sidhant Chopra³, Jack Rogers⁴, Maria Regina Dauvermann⁴, Scott Richard Clark^{5

6}

Affiliations

¹ Orygen, Parkville, VIC, Australia. kelly.allott@orygen.org.au.
² Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia. kelly.allott@orygen.org.au.
³ Department of Psychology, Yale University, New Haven, CT, USA.
⁴ Institute for Mental Health, University of Birmingham, Birmingham, UK.
⁵ University of Adelaide, Discipline of Psychiatry, Adelaide, SA, Australia.
⁶ Basil Hetzel Institute, Woodville South, SA, Australia.

Kelly Allott et al. Mol Psychiatry. 2024 Aug.

. 2024 Aug;29(8):2571-2574.

doi: 10.1038/s41380-024-02503-x. Epub 2024 Mar 7.

Kelly Allott^{1

2}, Sidhant Chopra³, Jack Rogers⁴, Maria Regina Dauvermann⁴, Scott Richard Clark^{5

6}

¹ Orygen, Parkville, VIC, Australia. kelly.allott@orygen.org.au.
² Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia. kelly.allott@orygen.org.au.
³ Department of Psychology, Yale University, New Haven, CT, USA.
⁴ Institute for Mental Health, University of Birmingham, Birmingham, UK.
⁵ University of Adelaide, Discipline of Psychiatry, Adelaide, SA, Australia.
⁶ Basil Hetzel Institute, Woodville South, SA, Australia.

No abstract available

Conflict of interest statement

The authors declare no competing interests.

1. Fatouros-Bergman H, Cervenka S, Flyckt L, Edman G, Farde L. Meta-analysis of cognitive performance in drug-naive patients with schizophrenia. Schizophrenia Res. 2014;158:156–62. - PubMed
1. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia. Is it a practice effect? Arch Gen Psychiatry. 2007;64:1115–22. - PubMed
1. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64:633–47. - PubMed
1. Husa AP, Rannikko I, Moilanen J, Haapea M, Murray GK, Barnett J, et al. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - An observational 9-year follow-up study. Schizophrenia Res. 2014;158:134–41. - PubMed
1. Allott K, Yuen HP, Baldwin L, O’Donoghue B, Fornito A, Chopra S, et al. Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial. Transl Psychiatry. 2023;13:199. - PMC - PubMed